Sun Pharma and Philogen complete patient enrollment for Phase III soft tissue sarcoma trial
Express Pharma
FEBRUARY 9, 2025
Sun Pharmaceutical Industries and Philogen S.p.A. have completed patient enrollment in the Phase III FIBROSARC trial for Soft Tissue Sarcoma (STS). All ongoing trials for Fibromun, an investigational biopharmaceutical product, remain on track with their expected timelines. Dario Neri, CEO of Philogen, stated, We are highly encouraged by the progress of Fibromuns pivotal trials in both soft tissue sarcoma and glioblastoma.
Let's personalize your content